

Q2 2024 Earnings

Lielwolech

AUGUST 16, 2024

Disclaimer

This presentation ("Presentation") does not contain or constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of Alvotech (the "Company") to any person in the United States or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Any trademarks, servicemarks, trade names and copyrights of the Company and other companies contained in this Presentation are the property of their respective owners. Forward-Looking Statements

This Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate and Alvotech; (2) the ability to maintain stock exchange listing to future events or future financial or operating performance of the Company and may include, for example, the Company's expectations regarding capitalization through equity or debt financing, Alvotech's ability to maintain listing requirements, future growth, results of operations, performance, projections of future revenue and cash runway, competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, the re-inspection of the Company's manufacturing site by the FDA, the expectation that the FDA's facility inspection in March 2023 will also serve as the pre-license inspection for AVT04, potential approval, including for AVT02 and AVT04, by the FDA and other regulatory agencies, commercial launch of the Company's products and product candidates, including AVT02 in the U.S., the timing and progress of the announcement of clinical study results, the commencement of patient studies, regulatory approvals and market launches, the Company's partnerships, including with Teva and information about the market opportunity of the Company's pipeline products. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those

expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond the Company's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against the Company or others following the business combination between Alvotech Holdings S.A., Oaktree Acquisition Corp. II standards; (3) changes in applicable laws or regulations; (4) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (5) the Company's estimates of expenses and profitability; (6) the Company's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (8) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (9) the ability of the Company or its partners to enroll and retain patients in clinical studies; (10) the ability of the Company or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of the Company's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) the Company's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of the Company's current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) the Company's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) the Company's ability to manufacture sufficient commercial supply of its approved products: (16) the outcome of ongoing and

candidates; (17) the potential impact of the ongoing COVID-19 pandemic on the FDA's review timelines, including its ability to complete timely inspection of manufacturing sites; and (18) the may exclude items that are significant in understanding and impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, war in Ukraine and global geopolitical tension, and the ongoing and evolving COVID-19 pandemic on the Company's business, financial position, strategy and anticipated You should be aware that the Company's presentation of these milestones: and (19) other risks and uncertainties set forth in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in documents that the IFRS measures of financial results provide useful information to Company may from time to time file or furnish with the SEC. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other data about the Company's industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk. Nothing in this Presentation should be regarded as a representation by any person that the forwardlooking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements quantify certain amounts that would be required to be included will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this Presentation. Non-IFRS Financial Measures

This Presentation may include projections of certain financial measures not presented in accordance with International Financial Reporting Standards ("IFRS") including, but not limited

🔥 alvotech

future litigation regarding the Company's products and product to, Adjusted EBITDA and certain ratios and other metrics derived therefrom. These non-IFRS financial measures are not measures of financial performance in accordance with IFRS and assessing the Company's financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under IFRS. measures may not be comparable to similarly-titled measures used by other companies. The Company believes these nonmanagement and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company believes that the use of these non-IFRS financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company's financial measures with other similar companies, many of which present similar non-IFRS financial measures to investors. These non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-IFRS financial measures. Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from these projected measures, together with some of the excluded information not being ascertainable or accessible, the Company is unable to in the most directly comparable IFRS financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable IFRS measures is included and no reconciliation of the forward-looking non-IFRS financial measures is included. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

Agenda

- 1 OVERVIEW
- **2** COMMERCIAL UPDATE
- **3** FINANCIAL UPDATE
- 4 Q&A

ROBERT WESSMAN Chairman and Chief Executive Officer

— Chief Commercial Officer

JOEL MORALES

Chief Financial Officer

MING LI

Chief Strategy Officer

BENEDIKT STEFÁNSSON

VP of IR and Global Communication

\rm Alvotech

Robert Wessman

Chairman and Chief Executive Officer



Strong Start to 2024



Key Highlights 1H-2024

1H <u>and</u> Q2 delivered positive adjusted EBITDA for the first time in company's history

→ 84% of total revenue in the period from 2nd quarter

Results driven by;

- → Global launches of AVT04, biosimilar to Stelara®
- → U.S. launch of AVT02, biosimilar to Humira®
- → Advancement of portfolio and pipeline
- → New commercial partnership arrangements

1H 2024 Performance



\$235.6mn







\$65.9mn

vs. \$22.7mn in 1H-23



vs. to \$20.3mn in 1H-23

\$63.5mn

vs. (\$146.7mn) loss in 1H-23


Milestone Revenues



\$169.7mn

vs. (\$2.5mn) in 1H-23

Continued Progress and Execution (2024)



A alvotech

Continued Evolution of Alvotech



PORTFOLIO GROWTH AND DIVERSIFICATION

47 Unique launches achieved across 2 biosimilars

Expect at least 70 unique launches before end of '25 from AVT04 or AVT02

3 BLA submissions expected in '24

Certain launches from new molecules expected before end of '25



No increase in headcount '24 vs. '23 despite;

- >3x increase in manufacturing output
- Record level of pipeline activity

\rm Alvotech Anil Okay **Chief Commercial Officer**

Commercialization of Humira Biosimilar in the U.S.



PRIVATE LABEL



- ♂ Commercialization agreement with Quallent, part of the Cigna network
- ✓ Product is available at \$0 out of pocket cost through Accredo specialty pharmacy
- ✓ ~20% of CIGNA Humira book converted to biosimilars in ~5 weeks¹

SIMLANDI FORMULARY



- 𝒞 SIMLANDI[®] is interchangeable to the reference product
- 𝞯 Soft launch in May targeted GPO/Hospital business
- Sector States St
- Economics remain the same as a 40/60 revenue share (Alvotech/Teva)

) ~1.3 million units of binding purchase orders for 2024 across both channels(US ONLY)

>80% of orders expected to be delivered in 2H, more weighted to Q4

AVT04 in the first wave in key markets



	CANADA	JAPAN	Europe	U.S.
Launch	Jamteki ustekinumab injection Launched March 2024	ウステキヌマブBS皮下注 シリンジTFJ Launched May 2024	Uzpruvo [®] solution for injection ustekinumab Launched July 2024	(ustekinumab-aekn) Expected February 2025
Partner		髲 Fuji Pharma Co., Ltd.	STADA	teva
Addressable Market	\$0.7Bn ¹	\$0.4Bn ¹	\$3.1Bn ¹	\$7Bn ²
Current Marketing Companies ³	Alvotech, Amgen	Alvotech	Alvotech, Sandoz	NA
Volume Trends ¹ CAGR% ('19-'23)	21%	21%	34%	19%
	(1) IQVIA (2) In I financial reports (MAT)			

(2)JnJ financial reports (MAT) (3)Based on public information

Pipeline Update

\rm Alvotech

EYLEA (aflibercept) Injection 2 mg AVT06

- Developing for both vial and pre-filled syringe
- Section 2018 Expect to seek interchangeability designation
- ✓ Partnership with Advanz Pharma for EU finalized in June '24
- Marketing application accepted by EMA with decision expected Q3, 2025
- ✓ Further announcements expected for other markets in '24



- Partnership with Advanz Pharma for EU finalized in June '24

AVT29

- 𝞯 Other partners include Teva (US)
- Formulation and process have been developed and program currently in scale-up phase





- Targeting both Simponi[®] (pharmacy benefit) and Simponi Aria[®] (medical benefit)
- Section 2017 Secti
- ✓ Only one other company has completed a clinical trial utilizing a biosimilar candidate
- Alvotech is the only known company to have biosimilars for Humira[®], Stelara[®] and an advanced program for Simponi[®] in major markets
- 𝞯 Expect filing in 2024

Pipeline Update (continued)



omalizumab AVT23

- ✓ Biosimilar candidate to Prolia[®] and Xgeva[®]
- ♂ High potential in women health
- Partnership with Dr. Reddy's Laboratories finalized in May '24 for the U.S. and European market¹
- Partnership with STADA in Europe finalized in June '24¹

- ✓ Biosimilar candidate to Xolair[®]
- Licensed from Kashiv
 BioSciences
- Growing market and limited competition
- Partnered with Advanz; agreement covers 27 countries of the European union, the UK, Australia, Canada and New Zealand
- 𝞯 Successful Phase 1 study
- ✓ Completion of enrollment for Phase III Clinical trial announced in July 2025



- ✓ Biosimilar candidate to Entyvio[®]
- Steadily growing biologic leading in IBD
- Clinical phase initiated; pilot safety study complete
- Ist dosing in patient trial expected in September 2024



AVT33

A alvotech

- ✓ Biosimilar candidate to Keytruda[®]
- Rapidly growing \$27 Bn¹ oncology biologic
- ✓ At-scale production planed for 2025; initiating tech transfer
- ♂ Concurrently, finalizing clinical design
- ✓ First subject dosing in clinical trial expected in late 2025
- Partnership for AVT33 remains in active discussion with multiple parties

\rm Alvotech

Joel Morales

Chief Financial Officer



Closing of Private Financing Leads to More Simplified Capital Structure



- ✓ SOFR based facility vs. previous fixed rate debt
- ✓ Removes short dated maturities
- ✓ Favorable call features
- ✓ All convertible bonds converted/redeemed
- ✓ Provides substantial cash to the balance sheet
- Remaining debt includes new term loan facility, mortgage, and equipment financing



1H 2024 Financial Highlights



OPERATING PERFORMANCE

- ✓ Total revenue of \$236 million, over 10x increase versus prior year.

- ✓ Adjusted EBITDA of \$64 million, versus negative (\$147) million in prior year.



CASH AND LIQUIDITY

- ✓ Finalized financing facilities providing net proceeds of \$142 million.
- ✓ Giving effect to the financing, \$178 million of proforma cash on hand as of June 30, including \$25 million of restricted cash.
- Sufficient cash runway to free cash flow positive.


SHARES OUTSTANDING

A alvotech

- ✓ Includes 39.6 million of earnout shares, of which 19.2 million not currently vested.
- Giving effect to the conversion of Convertible Bonds on July 1st, 301.5 million proforma shares outstanding as of June 30.
- Excludes shares to be issued for certain programs and arrangements that are not yet settled as of June 30.


Key Drivers of 2024 Outlook

\rm Alvotech





Reported to Adjusted Reconciliation





H1 2024 Adjustment	H1 2024 Adjustment Entries				
Cost of Product Revenue	 \$0.5m charge related to long-term incentive plan 				
R&D	 \$1.4m charge related to long-term incentive plan (non-cash) (\$0.6m) IP litigation costs attributable to programs - reclassified from G&A 				
G&A	 \$3.3m charge related to long-term incentive plan (non-cash) \$0.6m IP litigation costs attributable to programs - reclassified to R&D 				
Impairment loss on inv. in JV	 \$1.8m from sales of China JV 				
Finance Income	 (\$79.1m) fair value adjustment on derivatives (non-cash) 				
Finance Costs	 \$130.4m fair value adjustment on derivatives (non-cash) \$63.1m loss on remeasurement of bonds (non-cash) 				
Exchange Rate Differences	 (\$7.7m) impact of exchange rate fluctuations (non-cash) 				
Income Tax	 \$0.5m tax impact of discrete adj. in jurisdictions where tax benefits are available 				
H1 2023 Adjustment E	intries				
Cost of Product Revenue	 \$1.8m charge related to long-term incentive plan (non-cash) \$0.3m impairment and loss on sale of fixed asset 				
R&D	 \$18.5m of one-time, Biosana accounts receivables reserve pertaining to the termination of AVT-23 (non-cash) \$2.6m charge related to long-term incentive plan (non-cash) (\$1.3m) IP litigation costs attributable to programs - reclassified from G&A 				
G&A	 \$0.9m of one-time costs in connection with the Iceland main board listing \$1.3m IP litigation costs attributable to programs - reclassified to R&D \$7.5m charge related to long-term incentive plan (non-cash) 				
Finance Income	 (\$119.5m) fair value adjustment on derivatives (non-cash) 				
Finance Cost	 \$5.9m fair value adjustment on derivatives (non-cash) 				
Exchange Rate Differences	 \$3.1m impact of exchange rate fluctuations (non-cash) 				
Income Tax	 (\$4.5m) tax impact of discrete adjustments in jurisdictions where tax benefits are available 				

Capital Structure as of June 30, 2024



Common Shares Outstanding as of 30 June 2024 (in millions)	279.4
Issued shares (from convertible bonds) ¹	22.1
Pro Forma Common Shares Outstanding as of 1 July 2024 (in millions)	301.5
Potential future dilution:	
OACB Private Warrants ²	0.7
OACB Public Warrants	5.3
RSUs	2.7
Senior Bond Warrants	0.2
TOTAL POTENTIAL FUTURE DILUTION	8.9

TOTAL POTENTIAL FUTURE DILUTION

¹On 26 June 2024, the Company announced that all holders of the Tranche A and some holders of the Tranche B of the 2022 Convertible Bonds exercised their right to conversion into ordinary shares at the fixed conversion price of \$10.00 per share on the last scheduled conversion date prior to

maturity, which is 1 July 2024. Based on the current exchange rate, a total of approximately 22.1 million new shares were issued on 1 July 2024, corresponding to approximately \$221.1 million of aggregate value of these bonds with accrued interest.

² Using the Company's average stock price of \$13.52 and calculated in accordance with the Warrant Agreement dated September 21, 2020.





\rm A alvotech

Additional information

investors.alvotech.com

alvotech.com

alvotech.is

alvotech.ir@alvotech.com

in @ F

